AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 115 Posts
1 2 3 ... 8
AstraZeneca's Asthma Candidate Shows Promising Results
Article By: Zacks Investment Research Tuesday, September 12, 2017 12:33 PM EDT
AstraZeneca Plc. announced a subgroup analysis from SIROCCO and CALIMA phase III studies. The studies revealed the efficacy of benralizumab and also showed that this antibody provides increased benefits to patients.
In this article: AZN Also: SNY, REGN
Astrazeneca, Amgen Phase IIb Trial Of Tezepelumab Met Primary Endpoint
Article By: The Fly Thursday, September 7, 2017 8:20 AM EDT
AstraZeneca and Amgen announced results from the Pathway Phase IIb trial of tezepelumab that they say "showed a significant reduction" in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma.
In this article: AZN, AMGN
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson's Collaboration
Article By: Samuel Rae Thursday, August 31, 2017 12:48 PM EDT
AstraZeneca announced that it has put together a deal with Takeda Pharmaceutical Company Limited that will see the two collaborate on the development of a brand-new Parkinson's disease asset.
In this article: AZN, TKPYY Also: RHHBY, PRTA
AstraZeneca And Takeda Ink Deal To Develop Parkinson's Drug
Article By: Zacks Investment Research Wednesday, August 30, 2017 3:10 PM EDT
AstraZeneca PLC and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341.
In this article: AZN Also: RHHBY, ACOR, PRTA
Citi Sees Advantage For Tesaro Despite Broad Lynparza Label
Article By: The Fly Friday, August 18, 2017 6:00 AM EDT
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro.
In this article: AZN, TSRO Also: CLVS
AstraZeneca Plunges Following Failed Lung Cancer Study
Article By: The Fly Thursday, July 27, 2017 2:34 PM EDT
Shares of AstraZeneca are dropping sharply after the company said its MYSTIC trial failed to show its two-drug combination extended progression-free survival compared with standard-of-care chemotherapy for lung cancer patients.
In this article: AZN Also: MRK, TEVA, BMY
AstraZeneca Says Phase III MYSTIC Trial Did Not Meet Primary Endpoint
Article By: The Fly Thursday, July 27, 2017 7:29 AM EDT
The combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving PFS compared to SoC in patients whose tumors express PD-L1 on 25% or more of their cancer cells.
In this article: AZN
Three Large Cap Pharma Stocks To Buy Now
Article By: Zacks Investment Research Wednesday, July 12, 2017 5:20 AM EDT
While investors might think that the uncertainty of health care reform would bring volatility into the sector, we’ve actually seen healthcare stocks have a pretty decent year so far. The overall “Medical” sector is up about 11.9% year-to-date.
In this article: AZN, BAYRY, HLUYY
Hot Options Report: End Of Day - Monday, July 10
Article By: The Options Insider Monday, July 10, 2017 10:29 PM EDT
Most active stock options for end of day Monday: BAC, ASH, X, CSX, ICE, AAPL, CBI, NVDA and AZN.
In this article: ASH, AZN, BAC, CBI, CSX, ICE, X, AAPL, NVDA
Week In Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid
Article By: ChinaBio® Today Saturday, July 1, 2017 7:14 PM EDT
Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinovac is a Beijing vaccine company with legacy vaccines for hepatitis A and B.
In this article: AZN, GE, SVA, HCM
AstraZeneca: 4% Dividend Yield And A Pipeline To Emerging Market Growth
Article By: SureDividend Thursday, June 15, 2017 11:35 AM EDT
AstraZeneca’s strong pipeline and heavy presence in the emerging markets lay the groundwork for future growth.
In this article: AZN Also: JNJ, ABT
AstraZeneca Enters Agreement With Grunenthal To Divest Rights To Zomig
Article By: The Fly Wednesday, June 7, 2017 12:10 PM EDT
AstraZeneca announced that it has entered an agreement with Grunenthal for the global rights to Zomig outside Japan.
In this article: AZN, IPXL
Week In Review: Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
Article By: ChinaBio® Today Saturday, May 20, 2017 11:46 AM EDT
Shanghai Pharma may bid $4 billion to acquire Stada Arzneimittel, a German generic drugmaker. Stada has already accepted a similar offer from a consortium formed by two private equity firms -- Bain and Cinven.
In this article: AZN, LLY
E AstraZeneca Achieves Positive Phase 3 Results In Late Stage Cancer Trial
Article By: Terry Chrisomalis Sunday, May 14, 2017 3:52 AM EDT
On Friday, AstraZeneca announced that it had achieved positive results in a phase 3 lung cancer study. The key drug used in the trial, Imfinzi, was shown to greatly cut the risk of death in lung cancer patients.
In this article: AZN Also: MRK
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
1 to 16 of 115 Posts
1 2 3 ... 8